Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

J Cancer 2024; 15(8):2424-2430. doi:10.7150/jca.92202 This issue Cite

Research Paper

CFL1 is Implicated in Chronic Myeloid Leukemia Response during Imatinib Therapy

Xiufeng Yin1, Xia Li2, Hao Jiang1, Xiangjie Lin2, Zhixin Ma3,4, Xiaochang Chen1, Qibei Teng1, Jin Zhang1✉, Jie Jin2,5

1. Department of Hematology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, P R China.
2. Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, P R China.
3. Department of Laboratorial Medicine, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, P R China.
4. Clinical Prenatal Diagnosis Center, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, P R China.
5. Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, P R China.

✉ Corresponding author: Jin Zhang, Department of Hematology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, P R China. No.3 Qingchun East Road, Hangzhou 310003. jeanzhangedu.cn.

Citation:
Yin X, Li X, Jiang H, Lin X, Ma Z, Chen X, Teng Q, Zhang J, Jin J. CFL1 is Implicated in Chronic Myeloid Leukemia Response during Imatinib Therapy. J Cancer 2024; 15(8):2424-2430. doi:10.7150/jca.92202. https://www.jcancer.org/v15p2424.htm
Other styles

File import instruction

Abstract

Graphic abstract

Cofilin (CFL1) is one critical member of the actin deploy family (ADF). Overexpression of CFL1 is associated with aggressive features and poor prognosis in malignancies. We evaluated the expression of CFL1 in patients with chronic myeloid leukemia in the chronic phase (CML-CP), acute myelocytic leukemia (AML) and healthy controls. The role of CFL1 in imatinib therapy was also investigated using cell line. We found that the expression of CFL1 was lower in CML patients than that in healthy controls, and was significantly upregulated after imatinib therapy (p<0.05). CML patients with lower CFL1 achieved higher Major molecular response (MMR) rate after 6 months of imatinib therapy (p<0.05). Cofilin, P-cofilin and F-actin, especially branched F-actin were all upregulated after imatinib therapy. The lower CFL1 expression before treatment may predicts a better response to imatinib. Imatinib affects F-actin remodeling in CML patients by regulating CFL1 expression and activity.

Keywords: Chronic myeloid leukemia, Prognostic value, Imatinib mesylate, CFL1, F-actin

Citation styles

APA
Yin, X., Li, X., Jiang, H., Lin, X., Ma, Z., Chen, X., Teng, Q., Zhang, J., Jin, J. (2024). CFL1 is Implicated in Chronic Myeloid Leukemia Response during Imatinib Therapy. Journal of Cancer, 15(8), 2424-2430. https://doi.org/10.7150/jca.92202.

ACS
Yin, X.; Li, X.; Jiang, H.; Lin, X.; Ma, Z.; Chen, X.; Teng, Q.; Zhang, J.; Jin, J. CFL1 is Implicated in Chronic Myeloid Leukemia Response during Imatinib Therapy. J. Cancer 2024, 15 (8), 2424-2430. DOI: 10.7150/jca.92202.

NLM
Yin X, Li X, Jiang H, Lin X, Ma Z, Chen X, Teng Q, Zhang J, Jin J. CFL1 is Implicated in Chronic Myeloid Leukemia Response during Imatinib Therapy. J Cancer 2024; 15(8):2424-2430. doi:10.7150/jca.92202. https://www.jcancer.org/v15p2424.htm

CSE
Yin X, Li X, Jiang H, Lin X, Ma Z, Chen X, Teng Q, Zhang J, Jin J. 2024. CFL1 is Implicated in Chronic Myeloid Leukemia Response during Imatinib Therapy. J Cancer. 15(8):2424-2430.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use